首页> 外文期刊>Life sciences >Therapeutic strategies in Sickle Cell Anemia: The past present and future
【24h】

Therapeutic strategies in Sickle Cell Anemia: The past present and future

机译:镰状细胞贫血的治疗策略:过去的现在和未来

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Sickle Cell Anemia (SCA) was one of the first hemoglobinopathies to be discovered. It is distinguished by the mutation-induced expression of a sickle cell variant of hemoglobin (HbS) that triggers erythrocytes to take a characteristic sickled conformation. The complex physiopathology of the disease and its associated clinical complications has initiated multi-disciplinary research within its field. This review attempts to lay emphasis on the evolution, current standpoint and future scope of therapeutic strategies in SCA. (C) 2017 Elsevier Inc. All rights reserved.
机译:镰状细胞贫血(SCA)是首批被发现的血液管病之一。 它通过血红蛋白(HBS)的脉冲细胞变体的突变诱导的表达来区分,所述血红蛋白(HBS)的血红蛋白(HBS)触发红细胞以采取特征迹象的构象。 该疾病的复杂性质病理学及其相关的临床并发症已在其领域启动了多学科研究。 本综述试图强调SCA中的治疗策略的进化,当前的观点和未来范围。 (c)2017年Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号